A Blue Campaign On “WORLD AUTISM DAY”

Dr.Ashu Shah a philanthropist,
Entrepreneur & a Doctor said .Autism cause has inspired me to be A Philanthropist ,During my Internship period of time from Manipal Hospital Bangalore in 2007 we use to go for camping in a place called Swanthana
were Autism cases were more than other & I met a mother saying that Iam Drowning in Gratitude cos when i had ist child He was decleared a Autism,then second,then Third too was a cerbral palsy listening from her I really felt people are amazing,Why cant we too be one body part pain were whole body will start responding & Why cant we too Thank to our God for What we are .you know swallowing a Saliva is a blessing, Chewing food,Talking ,Walking is a blessing & Gratitude is an attitude, a mindset. It is recognising that the lens through which we view the world colours what we see. We can choose to focus on the things we dislike and, hence, feel hard done by. Or, we can choose to notice and appreciate the goodness in life, even when things are contrary to our wishes.

The miracle of gratitude is that it shifts our perception and transforms the way we see the world. The joy and happiness it generates within us is enough to slice through the challenges we may face.
I feel blessed, Amazing with Gratitude power completed my Ist project in 2007 Builded a 50 bedded A Special Cerebral palsy Centre with Multidisciplinary Team , Neurologist team & Speech therapist,occupational therapist ,Special Rehab.

Dr.Ashu Shah said:

Austism is primarily a genetic condition: Most of the risk for autism comes from genes1. Mutations in more than 100 genes are known to lead to the condition.
There are four types of tests that can detect these mutations, as well as structural variations that may lead to autism. More of the mutations they find have ties
Here’s a primer on how genetic tests work, their value for autism and what to expect from the results.
A genetic test cannot diagnose or detect autism. That’s because myriad genes along with environmental factors may underlie the condition. Roughly 100 genes have clear ties to autism, but no single gene leads to autism every time it is mutated.
For example, only about one in four people missing a stretch of chromosome 16 called 16p11.2 has autism. This and other mutations are also associated with other conditions, such as epilepsy or intellectual disability.
If a test reveals a harmful mutation with known ties to autism, the result could give the autistic person and her family an explanation for the condition. Some families also find emotional and practical support from others dealing with the same mutation.
There are no drugs tailored to particular autism mutations. But the mutations are often linked to other health problems, such as epilepsy, kidney problems or obesity, so having the information could help prevent or treat those problems.
There are four main types of tests. The oldest is karyotyping, the inspection of chromosomes under a microscope. This test reliably detects changes to segments larger than 10 million base pairs.
A test called chromosomal microarray analysis identifies duplications or deletions of DNA too small to show up on a karyotype. Still, a karyotype is necessary to identify instances in which chromosomes evenly trade a chunk of genetic material.
To detect even smaller duplications or deletions, and single base-pair swaps, clinicians must sequence or scan for mutations across single genes. Some clinicians use commercial autism tests that sequence a predetermined set of genes, but these panels often do not include top autism genes2.

An alternative is to sequence all of a person’s protein-coding DNA, or the exome. Clinicians may sequence the exomes of both parents as well as the child to find mutations present in only the child.

These spontaneous mutations are more likely to contribute to autism than are inherited ones. Exome sequencing is expensive, however, and often not covered by insurance.
Sequencing the entire genome is the most thorough method. It reveals mutations in any part of a person’s genome, not just the 1 percent that includes genes. It is still only a research tool, but as its price falls and it becomes more widely available, it could replace the other tests.
American medical academies recommend only karyotyping or chromosomal microarray analysis for autism. They also advise looking for point mutations in FMR1, MECP2 or PTEN, but only when a child shows other signs of the syndromes associated with mutations in these genes.

Relatively few. Karyotyping finds a relevant mutation in 3 percent of autistic people, and microarray analysis in 10 percent3. Sequencing the three genes associated with syndromes could identify an autism mutation in 14 percent of autistic people Combining these methods with sequencing the exome could yield results in as much as 40 percent of people with autism.
In one 2015 study, microarrays found mutations that could explain autism in 9 percent of children with the condition. Sequencing exomes revealed mutations in another 8 percent4.
The likelihood of finding a known genetic variant increases if the autistic person also has intellectual disability, seizures or unusual facial features.

What if a genetic test turns up nothing?
A negative result does not mean the person does not have a mutation that can cause autism. The test in question might not pick up that particular mutation, or perhaps the mutation does not yet have a known connection to autism.
Many of the genes linked to autism today were not associated with the condition five years ago. Most genetic testing facilities reanalyze results once a year based on the latest findings & its need Multi-disciplinary approach like Neurologist,reanalyzehhritis,Neuro Occupational therapist,Rehab NDT & special education to parents. sequencing, whole-genome sequencing
Counseling can ease shock of unexpected genetic results

#Bluecampiagn

City Today News

(citytoday.media)

9341997936

ಸೆನ್ಸೆಕ್ಸ್ ಮತ್ತು ನಿಫ್ಟಿ ಶೇಕಡ 4 ದಾಖಲು

ಬೆಂಗಳೂರು: ಸೆನ್ಸೆಕ್ಸ್ ಮತ್ತು ನಿಫ್ಟಿ ಹೂಡಿಕೆದಾರರಿಂದ ಭಾರಿ ಮಾರಾಟವನ್ನು ಕಂಡಿದ್ದರಿಂದ ಹಣಕಾಸು ವರ್ಷ 2021 ರ ಮೊದಲ ದಿನ ಕೆಂಪು ಬಣ್ಣದಲ್ಲಿತ್ತು. ಎರಡೂ ಮಾರುಕಟ್ಟೆಗಳು ಇಂದು ಕೆಳಮಟ್ಟದಲ್ಲಿ ತೆರೆದವು ಮತ್ತು ಮುಕ್ತಾಯದ ಘಂಟೆಯೊಂದಿಗೆ ಶೇಕಡ 4 ರಷ್ಟು ಮತ್ತಷ್ಟು ಕುಸಿದವು ಎಂದು ಏಂಜಲ್ ಬ್ರೋಕಿಂಗ್ ಲಿಮಿಟೆಡ್ ಸಂಸ್ಥೆಯ ಹೆಡ್ ಅಡ್ವೆಂಸರಿ ಆಮರ್ ದಿಯೋ ಸಿಂಗ್ ಹೇಳಿದರು.

ಐಟಿ ಮತ್ತು ಬ್ಯಾಂಕಿಂಗ್ ಷೇರುಗಳು ಮಾರುಕಟ್ಟೆಯ ಕೆಳಕ್ಕೆ ಇಳಿಯಲು ಹೆಚ್ಚಿನ ಕೊಡುಗೆ ನೀಡಿವೆ. ಟೆಕ್ ಮಹೀಂದ್ರಾ, ಟಿಸಿಎಸ್, ಮತ್ತು ಮೈಂಡ್‌ಟ್ರೀ ಸೇರಿದಂತೆ ಉನ್ನತ ಐಟಿ ಆಟಗಾರರು ಇಂದು 9.5% ರಷ್ಟು ಕುಸಿದಿದ್ದಾರೆ. ಕೊಟಕ್ ಬ್ಯಾಂಕ್ (ಎನ್‌ಎಸ್‌ಇ) ಕೂಡ ಶೇಕಡ 8.83 ರಷ್ಟು ಕುಸಿದಿದೆ.

ಎಲ್ಲಾ ಮಾರುಕಟ್ಟೆ ಪ್ರಸ್ತುತ ಪ್ರವೃತ್ತಿಗಳನ್ನು ಕೊರೊನಾ ವೈರಸ್ ಏಕಾಏಕಿ ನಡೆಸುತ್ತಿದೆ. ಭಾರತದಲ್ಲಿ ಕೋವಿಡ್-19 ಪ್ರಕರಣಗಳ ಸಂಖ್ಯೆಯಲ್ಲಿ ಏರಿಕೆ ಕಂಡುಬಂದಿದೆ. ಧಾರ್ಮಿಕ ಮೆರವಣಿಗೆಗಳು ಮತ್ತು ಸಾಮೂಹಿಕ ವಲಸೆಯಂತಹ ಘಟನೆಗಳು ಮುಂಬರುವ ಕೆಲವು ದಿನಗಳಲ್ಲಿ ಕೋವಿಡ್ ಪ್ರಕರಣಗಳು ಮತ್ತಷ್ಟು ಹೆಚ್ಚಾಗಬಹುದು ಎನ್ನುವ ಭೀತಿ ಮತ್ತಷ್ಟು ಹುಟ್ಟುಹಾಕಿದೆ. ಇದರ ನೇರ ಪರಿಣಾಮವನ್ನು ಷೇರು ಮಾರುಕಟ್ಟೆಯೊಳಗಿನ ಹೂಡಿಕೆದಾರರ ಮನೋಭಾವದ ಮೇಲೆ ಕಾಣಬಹುದು.

ಕೊರೊನಾ ವೈರಸ್ ಲಾಕ್‌ ಡೌನ್ ಬಳಿಕ ವಾಹನ ಮಾರಾಟದಲ್ಲಿ ತೀವ್ರ ಕುಸಿತ ಕಂಡುಬಂದಿದೆ. ಭಾರತದ ಅತಿದೊಡ್ಡ ಆಟೋಮೊಬೈಲ್ ಸಂಸ್ಥೆ ಮಾರುತಿ ಸುಜುಕಿ ಫೆಬ್ರವರಿಯಲ್ಲಿ 158,076 ಯುನಿಟ್‌ಗಳಿಂದ ಮಾರ್ಚ್ ತಿಂಗಳಲ್ಲಿ 83,792 ಯುನಿಟ್‌ಗಳಿಗೆ ಇಳಿದಿದೆ. ಅಶೋಕ್ ಲೇಲ್ಯಾಂಡ್ ಮಾರ್ಚ್ ನಲ್ಲಿ ಶೇಕಡ 90 ಕ್ಕಿಂತಲೂ ಕಡಿಮೆಯಾಗಿದೆ. ಪರಿಣಾಮ ಆಟೋ ಸೂಚ್ಯಂಕ ಕೆಂಪು ಬಣ್ಣದಲ್ಲಿತ್ತು, ನಿಫ್ಟಿ ಆಟೋ ಸೂಚ್ಯಂಕ ಶೇಕಡ 1.56 ಮತ್ತು ಬಿಎಸ್ಇ ಆಟೋ ಸೂಚ್ಯಂಕ ಶೇಕಡ 1.54 ರಷ್ಟು ಕುಸಿಯಿತು. ಹೀರೋ ಮೊಟೊಕಾರ್ಪ್, ಬಜಾಜ್ ಆಟೋ, ಮತ್ತು ಎಕ್ಸೈಡ್ ಇಂಡಸ್ಟ್ರೀಸ್ ಸೇರಿದಂತೆ ಕೆಲವೇ ಕೆಲವು ಆಟೋ ಸ್ಟಾಕ್‌ಗಳು ಇಂದು ವಿರುದ್ಧ ದಿಕ್ಕಿನಲ್ಲಿ ನಡೆದಿವೆ.

ಮಾರ್ಚ್ ನಲ್ಲಿ ಎಫ್ಪಿಐಗಳು ಭಾರತೀಯ ಇಕ್ವಿಟಿ ಮಾರುಕಟ್ಟೆಯಿಂದ 9 15.9 ಬಿಲಿಯನ್ ದಾಖಲೆಯನ್ನು ಹೊರಹಾಕಿದವು. ಈ ಎಫ್‌ಪಿಐ ಹೊರಹರಿವು ಏಷ್ಯಾದಲ್ಲಿ ಅತಿ ಹೆಚ್ಚು ಮತ್ತು ಮಾರುಕಟ್ಟೆಯನ್ನು ಕೆಳಕ್ಕೆ ಎಳೆದಿದೆ. ಮುಂಬರುವ ಕೆಲವು ದಿನಗಳಲ್ಲಿ ಭಾರತದಲ್ಲಿನ ನಿಯಂತ್ರಣ ಕ್ರಮಗಳಿಗೆ ಎಫ್‌ಪಿಐಗಳು ಹೇಗೆ ಪ್ರತಿಕ್ರಿಯಿಸುತ್ತವೆ ಎಂಬುದನ್ನು ನೋಡಲು ಇದು ನಿರ್ಣಾಯಕವಾಗಿರುತ್ತದೆ.

ಪ್ರಮುಖ ಸೂಚ್ಯಂಕಗಳು ಶೇಕಡ 5 ನಷ್ಟು ಕುಸಿದಿದ್ದರಿಂದ ಇಂದು ಇಡೀ ಏಷ್ಯಾದ ಮಾರುಕಟ್ಟೆಗೆ ಇದು ಕೆಟ್ಟ ದಿನವಾಗಿತ್ತು. ಪ್ಯಾನ್-ಯುರೋಪಿಯನ್ ಎಸ್‌ಟಿಒಎಕ್ಸ್ಎಕ್ಸ್ 600 ರೊಂದಿಗೆ ಯುರೋಪಿಯನ್ ಮಾರುಕಟ್ಟೆಗಳಲ್ಲಿ ಒತ್ತಡವು ಶೇಕಡ 3.2 ರಷ್ಟು ಕುಸಿದಿದೆ. ಯುಎಸ್ ಸಾವಿನ ಕಠೋರ ದೃಷ್ಟಿಕೋನದಿಂದಾಗಿ ವಾಲ್ ಸ್ಟ್ರೀಟ್ ಫ್ಯೂಚರ್ಸ್ ಸಹ ಶೇಕಡ 3.1 ಕಡಿಮೆ ವಹಿವಾಟು ನಡೆಸಿತು.

City Today News

(citytoday.media)

9341997936

Kindly Stay at Home to Save Your Precious life, Suffer Now & Enjoy Later. Staying at Home is the One and Only Option.

The lockdown is absolutely essential, but essential services should not suffer. Isolation is the best thing we can do now. Let us look at it step-wise. First, we have to work on prevention. What are the maximum precautions a person can take? Other than isolation people talk of sanitisation. I accept that. If you are sanitising your hands why aren’t you sanitizing inside your nose and mouth and inside your lungs? In my personal opinion steam inhalation twice a day is advisable, it doesn’t cost anything, in addition to that gargling once a day with Listerine is also good since alcohol kills viruses.


Dear, Brother’s, Sisters’s, Friends & Relatives,
Kindly Stay at Home to Save Your Precious life, Suffer Now & Enjoy Later. Staying at Home is the One and Only Option.

I Request One & all With Folded Hand To Stay at Home.

Gs. Gopalraaj
Editor- City Today News 9341997936

Takeda Appoints New Country Head for India

·         Koki Sato to lead Takeda’s business in India, ensuring patient access to highly innovative medicines

·         Seasoned biopharmaceutical leader with over 17 years of experience across geographies

01 April, 2020: Takeda India announced today the appointment of Koki Sato as the Country Head for the Company’s India business. In his current capacity, he will lead the company’s operations with a focus on the expansion of patient access to Takeda’s highly innovative portfolio in the country.

Koki joined Takeda in 2003 and, since then, grew within the company to hold various senior international roles across multiple functions, including Commercial Operations, Finance, and HR. Prior to this role, Koki was the General Manager of Ukraine, Belarus, and Moldova (UBM) Cluster in Takeda’s ICMEA* Area.

Commenting on his new role, Koki Sato said, “India is of significant importance for Takeda and we endeavor to develop initiatives which will lead to enhanced patient access to our highly innovative medicines locally. We remain committed to serving India’s patients, and aim to bring newer therapies for rare diseases, gastroenterology, and oncology to them in the coming years, along with hopefully, our Dengue vaccine candidate.”

Across its ICMEA* Area, and more broadly across the countries that span its Growth & Emerging Markets Business Unit, Takeda collaborates with healthcare providers, governments and regulators, to ensure that its portfolio of innovative medicines is made available to patients as quickly and safely as possible.

Koki will be officially assuming his position from April 1, 2020. He is a Japanese national and holds a Bachelor of Arts degree in Political Science and Economics from Waseda University, Japan.

ICMEA: India, the Commonwealth of Independent States, the Middle East (including Turkey), & Africa

– ENDS –

About Takeda India

Takeda India is part of Takeda Pharmaceutical Company Limited’s group of companies, headquartered in Japan. In the country, the company currently focuses on the therapeutic areas of Rare Diseases, including Hemophilia and Lysosomal Storage Disorders and plasma-derived therapies. Takeda has a presence across the Indian subcontinent, including in Sri Lanka, Nepal, and Bangladesh.

About Takeda Pharmaceuticals

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (G.I.), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com

Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Portal Instruments nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

City Today News

(citytoday.media)

9341997936

5 Students of LISAA Design Celine Dion’s Red Carpet Dress Replica

5 Final Year Fashion Students of LISAA School of Design, a premier fashion school have designed Red Carpet dress worn by Canadian Pop Singer , Celine Dion .

The name of the design students are Parnika, Vidushi, Athira, Smriti and Kritika . These students were given a certificate of appreciation by the institute and the cost of the fabric was covered by the institute itself.

“Being teamed up with classmates made it both fun and efficient. We were able to strategically use each one’s refined skill and accomplish the task.” says Parnika.

“The brains of some, the patience, sensibility and neatness of the others had enabled the division of work to be very simple. Everyone knew their part and there was no need to worry about the outcome,” adds Vidushi, Final Year Student.

Athira further adds, “Moreover, all of us adored the design and hence put wholesome effort to ensure that our version of it would be just as elegant and charming as the original.”

“Right from figuring the construction and patterns multiple times, to choosing the fabric, to dealing with the length and bulk of the garment, which although seemed simple, had been quite challenging,” recounts Smriti, Final Year Student.

“This task also enabled us to learn the intricacies of haute couture, which is essential with our upcoming individual couture collections. We managed to do our job, whilst having an overwhelming experience, making it an endeavor we shall all always remember,” says Kritika , Final Year Student .

The teachers of the Pattern Making Department who helped out the students in re-creating the dress said,
‘Through our years of experience ,each time re-creation project brings in new surprise and challenges to out do the past work.
Huge volume requires meterage from 30 to 250 meters , manipulating such scale is not only cumbersome but to validate a new beginning.’

Avi Keswani, Founder & Director, LISAA School of Design says, “It was an assignment part of the curriculum known as the Re-creation project to understand the importance of Haute Couture and how to replicate phenomenal couture designs of iconic designers. It took our students about 1.5 months to complete this entire garment as a group project .The materials used were satin and the technique of boning was used for corset. ”

City Today News

(citytoday.media)

9341997936